| abstract |
The prevent invention provides a compound of formula (I): ##STR1## wherein Ar is (a) phenyl, naphthyl and biphenyl, each optionally substituted with C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 hydroxyalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, C 2-4 alkoxyalkoxy, C 1-4 alkylthio, hydroxy, halo, cyano, amino, C 1-4 alkylamino, di (C 2-8 ) alkylamino, C 2-6 alkanoylamino, carboxy, C 2-6 alkoxycarbonyl, or optionally substituted phenyl, phenoxy, phenylthio or phenylsulfinyl or (b) furyl, benzo b!furyl, thienyl, benzo b!thienyl, pyridyl or quinolyl, each optionally substituted with C 1-4 alkyl, C 1-4 haloalkyl, halo, C 1-4 alkoxy, optionally-substituted phneyl, phenoxy or phenylthio, X is C 1 -C 4 alkylene, C 2 -C 4 alkenylene, --(CHR 1 ) m --Q 1 --(CHR 2 ) n --, --O--(CHR 1 ) j --Q 2 -- and --(CHR 1 )--O--N═ in which the N═ moiety is attached to the cycloalkene ring; and in which Q 1 is O, S, SO, SO 2 , NR 3 , CH═N--O or CO, Q 2 is O, S, SO, SO 2 or NR 3 , and R 1 , R 2 and R 3 are each hydrogen or C 1 -C 4 alkyl, m and n are each an integer from 0 to 4 and j is an integer from 1 to 4; p is an integer of 1 or 2; Y is hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 2-4 alkoxyalkyl, C 1-4 alkylthio, hydroxy, halo, cyano or amino; Z is hydrogen or C 1-4 alkyl; and M is hydrogen, a pharmaceutically acceptable cation or a pharmaceutically acceptable metabolically cleavable group. n Further the invention provides a pharmaceutical composition for treating a medical condition for which a 5-lipoxygenase inhibitor is needed in a mammalian subject which comprises a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. Preferably the medical condition is an inflammatory disease, allergy or cardiovascular diseases. |